Radio and PodcastRadio and PodcastLive Radio & Podcasts
SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing artwork
Science & Medicine

SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing

Oncotarget by Oncotarget Podcast

Apr 21, 202600:05:40Science & Medicine

Cancer has long been understood through a variety of biological frameworks, including genetic mutations, dysregulated signaling pathways, and uncontrolled cell proliferation. Yet, these models often capture the visible c...

About This Episode

SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing is an episode from Oncotarget by Oncotarget Podcast. Cancer has long been understood through a variety of biological frameworks, including ge...

Podcast

This episode belongs to Oncotarget.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Apr 21, 2026, 00:05:40 long, audio available.

Questions About This Episode

What is SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing about?

Cancer has long been understood through a variety of biological frameworks, including genetic mutations, dysregulated signaling pathways, and uncontrolled cell proliferation. Yet, these models often capture the visible consequences of disease rather than the deeper metabolic dependencies that sustain tumor survival. Despite major advances in targeted therapies, a central challenge remains: what underlying mechanisms make cancer cells vulnerable to treatment, and how can these vulnerabilities be exploited more effectively? Increasing attention has shifted toward cellular metabolism—particularly lipid regulation and energy-sensing pathways such as AMPK—as critical determinants of tumor behavior. Scientists are now taking a closer look at how metabolism works together with stress responses like autophagy—and how this connection could be used to develop better cancer treatments. A new research paper was published in Volume 17 of Oncotarget, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” The study was led by first author Michael R. Booth and corresponding author Paul Dent from Virginia Commonwealth University, in collaboration with Laurence Booth and Jane L. Roberts from Virginia Commonwealth University and John M. Kirkwood from the University of Pittsburgh Cancer Institute. Full blog - Paper DOI - Correspondence to - Paul Dent - paul.dent@vcuhealth.org Abstract video - Sign up for free Altmetric alerts about this article -

Where can I listen to SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing?

You can listen to SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing from?

SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing is an episode from Oncotarget by Oncotarget Podcast.

How long is this episode?

This episode is 00:05:40 long.

When was this episode published?

This episode was published on Apr 21, 2026.

Can I save SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from Oncotarget?

Yes. This page shows related episodes from Oncotarget when more episodes are available from the podcast feed.